Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

NCT06220318 ↗

Phase 1/2 Active not recruiting 155 enrolled Fujian Haixi Pharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.

Timeline

Start: 2023-07-19
Primary completion: 2026-08-30
Completion: 2026-08-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	C019199	Unknown	100 mg	Oral
Subject	Sintilimab	Monoclonal antibody	200 mg	Intravenous

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications